Senti Bio reports Q1 net loss $4.2M, secures up to $40M financing; FDA supports pivotal trial for SENTI-202 in R/R AML

Senti Biosciences, Inc.

Net loss $4.2M ($0.14/share) vs $14.1M year ago; cash $8.9M as of March 31, 2026.
Secured up to $40M in senior secured convertible notes from Celadon Partners; initial $10M tranche expected May 2026.
FDA RMAT meeting supports single-arm multi-center pivotal trial for SENTI-202 in R/R AML after LD chemotherapy.
Donor X phenotype identified: 50% cCR (7/14) with Donor X NK cells vs 12.5% (1/8) without; longest remission 21+ months.
Lease modification gain $6.9M; cash burn reduced to $7.5M Q1 2026 from $14.1M Q1 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Senti Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income $4.2 million, or $0.14 per basic and diluted share.

Period: the first quarter ended March 31, 2026
Net income: $4.2 million, or $0.14 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss was $4.2 million, or $0.14 per basic and diluted share, for the first quarter of 2026

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-034834

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.